#Clostridioides difficile Infection Study

[theloverstomb]

‘Fragile Microbiomes’ by bio-artist Anna Dumitriu

1. SYPHILIS DRESS- This dress is embroidered with images of the corkscrew-shaped bacterium which causes the sexually transmitted disease syphilis. These embroideries are impregnated with the sterilised DNA of the Nichols strain of the bacterium - Treponema pallidum subsp. pallidum - which Dumitriu extracted with her collaborators.

2. MICROBE MOUTH- The tooth at the centre of this necklace was grown in the lab using an extremophile bacterium which is part of the species called Serratia (Serratia N14) that can produce hydroxyapatite, the same substance that tooth enamel is made from.

The handmade porcelain teeth that make up this necklace have been coated with glazes derived from various bacterial species that live in our mouths and cause tooth decay and gum disease, including Porphyromonas gingivalis, which can introduce an iron-containing light brown stain to the glaze.

3. TEETH MARKS: THE MOST PROFOUND MYSTERY- In his 1845 essay “On Artificial Teeth”, W.H. Mortimer described false teeth as “the most profound mystery” because they were never discussed. Instead, people would hide the stigma of bad teeth and foul breath using fans.

This altered antique fan is made from animal bone and has been mended with gold wire, both materials historically used to construct false teeth (which would also sometimes incorporate human teeth). The silk of the fan and ribbon has been grown and patterned with two species of oral pathogens: Prevotella intermedia and Porphyromonas gingivalis. These bacteria cause gum disease and bad breath, and the latter has also recently been linked to Alzheimer’s disease.

4. PLAGUE DRESS- This 1665-style 'Plague Dress' is made from raw silk, hand-dyed with walnut husks in reference to the famous herbalist of the era Nicholas Culpeper, who recommended walnuts as a treatment for plague. It has been appliquéd with original 17th-century embroideries, impregnated with the DNA of Yersinia pestis bacteria (plague). The artist extracted this from killed bacteria in the laboratory of the National Collection of Type Cultures at the UK Health Security Agency.

The dress is stuffed and surrounded by lavender, which people carried during the Great Plague of London to cover the stench of infection and to prevent the disease, which was believed to be caused by 'bad air' or 'miasmas'. The silk of the dress references the Silk Road, a key vector for the spread of plague.

5. BACTERIAL BAPTISM- based on a vintage christening gown which has been altered by the artist to tell the story of research into how the microbiomes of babies develop, with a focus on the bacterium Clostridioides difficile, originally discovered by Hall and O’Toole in 1935 and presented in their paper “Intestinal flora in new-born infants”. It was named Bacillus difficilis because it was difficult to grow, and in the 1970s it was recognised as causing conditions from mild antibiotic-associated diarrhoea to life-threatening intestinal inflammation. The embroidery silk is dyed using stains used in the study of the gut microbiome and the gown is decorated with hand-crocheted linen lace grown in lab with (sterilised) C. difficile biofilms. The piece also considers how new-borns become colonised by bacteria during birth in what has been described as ‘bacterial baptism’.

6. ZENEXTON- Around 1570, Swiss physician and alchemist Theophrastus Paracelsus coined the term ‘Zenexton’, meaning an amulet worn around the neck to protect from the plague. Until then, amulets had a more general purpose of warding off (unspecified) disease, rather like the difference today between ‘broad spectrum’ antibiotics and antibiotics informed by genomics approaches which target a specific organism.

Over the next century, several ideas were put forward as to what this amulet might contain: a paste made of powdered toads, sapphires that would turn black when they leeched the pestilence from the body, or menstrual blood. Bizarre improvements were later made: “of course, the toad should be finely powdered”; “the menstrual blood from a virgin”; “collected on a full moon”.

This very modern Zenexton has been 3D printed and offers the wearer something that genuinely protects: the recently developed vaccine against Yersinia pestis, the bacterium that causes plague.

[mindblowingscience]

Researchers have developed a new antibiotic that reduced or eliminated drug-resistant bacterial infections in mouse models of acute pneumonia and sepsis while sparing healthy microbes in the mouse gut. The drug, called lolamicin, also warded off secondary infections with Clostridioides difficile, a common and dangerous hospital-associated bacterial infection, and was effective against more than 130 multidrug-resistant bacterial strains in cell culture. The findings are detailed in the journal Nature. "People are starting to realize that the antibiotics we've all been taking—that are fighting infection and, in some instances, saving our lives—also are having these deleterious effects on us," said University of Illinois Urbana-Champaign chemistry professor Paul Hergenrother, who led the study with former doctoral student Kristen Muñoz.

Continue Reading.

[nuadox]

A new study has shown that an mRNA vaccine protected mice against deadly intestinal C. difficile

- By Nuadox Crew -

Researchers have developed an mRNA vaccine targeting Clostridioides difficile (C. difficile), a severe intestinal pathogen responsible for about 30,000 deaths annually in the U.S.

This new vaccine showed promising results in mice, offering protection from severe illness and death after exposure to lethal doses of the bacteria.

Unlike conventional vaccines, the mRNA version triggered a broad immune response, including antibodies and T cells. Vaccinated mice survived, experiencing only mild symptoms, and maintained immunity for six months.

While the vaccine has yet to be tested on humans, early studies in rhesus macaques suggest it might also elicit an immune response in primates.

However, more research, including testing on "dirty mice" with more naturalistic immune systems, is needed before moving to human trials.

Header image: Clostridioides difficile pathogen. Credit: National Foundation for Infectious Diseases (NFID).

Read more at Science News

Scientific paper: Alameh, M., Semon, A., Bayard, N. U., Pan, Y., Dwivedi, G., Knox, J., Glover, R. C., Rangel, P. C., Tanes, C., Bittinger, K., She, Q., Hu, H., Bonam, S. R., Maslanka, J. R., Planet, P. J., Moustafa, A. M., Davis, B., Chevrier, A., Beattie, M., . . . Zackular, J. P. (2024). A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection. Science, 386(6717), 69–75. https://doi.org/10.1126/science.adn4955

Other recent news

Israel at COP29: Israel will showcase 20 climate-tech firms at the COP29 Climate Conference in Baku,Azerbaijan. These companies offer solutions in fields such as emissions, pollution, and carbon capture.

Revolutionary Super Polymer: Researchers at Osaka University have developed a new type of polymer that is unbelievably tough and endlessly recyclable.

Hubble's Galactic Masterpiece: The Hubble Space Telescope has unveiled a stunning image of NGC 5248, a spiral galaxy located 42 million light-years away.

Brain-Controlled Bionic Limbs: Advances in brain-controlled bionic limbs are inching closer to reality, offering new possibilities for individuals with mobility impairments.

[cfsremission]

Reviewing recent study on Fibromyalgia

This is based on this April 24,2035 paper: The gut microbiota promotes pain in fibromyalgia. There are two interesting finings: “transplantation of a healthy microbiota [FMT] is associated with reduced pain and improved quality of life. ” This option is rarely available since FMT is only authorized for  recurrent Clostridioides difficile infections And  “Since mice transplanted with the FM gut…

[gastroenterologyucgconferences]

Microbiome Research: Unlocking the Future of Gastroenterology

The Importance of the Gut Microbiome

Key Areas of Microbiome Research

1. Gut-Brain Axis Emerging studies reveal the bidirectional communication between the gut and the brain, known as the gut-brain axis. Research indicates that microbial imbalances can contribute to anxiety, depression, and other neurological conditions, making it a significant focus for interdisciplinary studies.

2. Microbiome and Immune Modulation The gut microbiome plays a pivotal role in regulating immune responses. Advances in research have shown how specific bacterial strains can modulate inflammation, opening doors for targeted therapies in conditions like Crohn’s disease and ulcerative colitis.

3. Microbiome in Cancer Prevention and Treatment Certain gut bacteria are linked to the development or prevention of colorectal cancer. Researchers are exploring how modulating the microbiome through diet, probiotics, or fecal microbiota transplantation (FMT) can serve as preventive or adjunctive cancer therapies.

4. Personalized Medicine With advancements in sequencing technologies, microbiome profiling is becoming an essential tool for personalized treatment plans. This approach tailors therapies to an individual’s unique microbiome composition, improving efficacy and reducing side effects.

Clinical Applications of Microbiome Research

1. Fecal Microbiota Transplantation (FMT) FMT has emerged as a breakthrough treatment for recurrent Clostridioides difficile infections. Ongoing trials are investigating its effectiveness in IBD, IBS, and other GI disorders.

2. Probiotics and Prebiotics Probiotic supplements and prebiotic-rich diets are being studied for their role in maintaining gut health and preventing dysbiosis. Advanced formulations now target specific conditions with remarkable precision.

Challenges and Future Directions

While microbiome research holds immense promise, challenges remain, including:

Limited understanding of the complex interactions within the microbiome.

Variability in results across different populations.

Ethical and regulatory concerns regarding microbiome-based therapies.

Future research aims to address these gaps, enabling the development of robust diagnostic tools and innovative treatments.

The Role of the 15th World Gastroenterology, IBD & Hepatology Conference

The 15th World Gastroenterology, IBD & Hepatology Conference will serve as a platform to discuss groundbreaking microbiome research. Highlights include:

Expert Sessions: Explore the latest findings on the gut-brain axis, microbiome-immune interactions, and personalized microbiome therapies.

Clinical Workshops: Gain hands-on experience in microbiome profiling and its clinical applications.

Research Presentations: Learn about emerging technologies and therapeutic strategies directly from global thought leaders.

Register Now to Be Part of the Future

Seize the opportunity to learn, network, and contribute to the evolving field of microbiome research.

Submit Your Abstract: https://gastroenterology.utilitarianconferences.com/submit-abstract

Register Here: https://gastroenterology.utilitarianconferences.com/registration

Visit the Official Website: https://gastroenterology.utilitarianconferences.com/

#MicrobiomeResearch #GutHealthInnovation #Gastroenterology2025 #GutBrainAxis #FMT #PersonalizedMedicine #IBDTherapies #GastroConference

[hardoctornews]

Inibitori della pompa protonica ed infezioni da C. difficile nei pazienti ospedalizzati

Secondo uno studio pubblicato sul Journal of Hospital Infection, il rischio di insorgenza di infezioni da Clostridioides difficile è più elevato nei pazienti ricoverati in ospedale che per trattare l’ulcera da stress utilizzano inibitori della pompa protonica rispetto a quello degli individui che assumono antagonisti del recettore H2 dell’istamina. “Studi precedenti sull’infezione…

[the365scriptcare]

Heartburn and acid reflux can be uncomfortable and disruptive, preventing people from enjoying their meals and sleeping well. A lot of people seek relief from Dexilant, a commonly utilized medicine. Although Dexilant works well, the cost may be a concern for people suffering from chronic problems. Fortunately, there are inexpensive choices that provide good heartburn relief. This article will define acid reflux and heartburn, explain how Dexilant works, and discuss cost-effective symptom control options.

Understanding Acid Reflux and Heartburn  

What Are Acid Reflux and Heartburn?  

Acid reflux occurs when stomach acid flows back up into the esophagus, the tube that connects the throat and stomach. This reverse movement can cause discomfort, resulting in a burning sensation in the chest, which is commonly referred to as heartburn.

Causes of Acid Reflux  

Acid reflux occurs when the lower esophageal sphincter (LES) fails to properly close. Some of the most common triggers include:

Eating large meals or lying down right after eating  

Consuming acidic, spicy, or fatty foods  

Drinking beverages like coffee, soda, or alcohol  

Smoking  

Stress or anxiety  

Risk Factors  

Obesity, pregnancy, and certain medical problems, such as hiatal hernia, can all increase the risk of developing acid reflux.

Emerging Insights on Acid Reflux  

According to recent study, various hereditary variables, such as LES muscle tone and esophageal sensitivity, may increase the likelihood of acid reflux. Gut microbiota has also been shown to play an important role in acid reflux. Disruptions in the gut microbiome can cause increased inflammation and acid production, resulting in the development of symptoms. This research could lead to novel treatments for gut health, such as probiotics and individualized dietary adjustments to maintain a healthy microbiome.

Impact on Long-Term Health  

Untreated persistent acid reflux can lead to esophagitis, Barrett’s esophagus, and even esophageal cancer. Recent research emphasizes the need of quick intervention in minimizing these risks. Avoiding long-term harm requires regular monitoring, lifestyle adjustments, and the use of appropriate drugs. This emphasizes the growing necessity of discovering cost-effective and easily accessible medicines for general health and well-being.

Dexilant: A Closer Look  

Dexilant (dexlansoprazole) is a proton pump inhibitor (PPI) that reduces acid production in the stomach. Dexilant lowers acid levels, protecting the esophagus and relieving heartburn symptoms.

Benefits of Dexilant  

Dual delayed-release technology gives longer relief, which can last up to 24 hours.  

Effective for treating GERD (gastroesophageal reflux disease) and repairing esophageal damage.  

Potential Side Effects  

Dexilant is effective, however it may cause headaches, nausea, diarrhea, or constipation. Prolonged use may lead to issues such as low magnesium levels or brittle bones.

The Cost Factor  

Dexilant’s high cost is justified by its efficacy. Those without insurance or limited coverage may find the monthly expense prohibitively expensive. This is when budget-friendly options become critical.

New Research on PPIs Like Dexilant  

Recent study has looked into the long-term health repercussions of using PPIs, including suspected links to kidney difficulties and an increased risk of certain infections such Clostridioides difficile (C. diff). These findings have generated discussions about being more cautious with the use of PPIs and ensuring they are only administered when necessary. This emphasizes the importance of considering cost-effective alternatives to avoid becoming overly reliant on a single medicine.

Emerging Benefits of Dexilant’s Mechanism  

Beyond symptom relief, research suggests that Dexilant’s dual delayed-release mechanism may offer other benefits. Its ability to regulate stomach acid levels over lengthy periods of time may be especially advantageous for people who suffer from severe nocturnal reflux or require esophageal repair. However, cheaper comparable medications with the same functionalities are already appearing, offering patients with cost-effective options for managing their money.

Affordable Alternatives to Dexilant  

Over-the-Counter Medications  

Antacids  

Antacids neutralize stomach acid, offering immediate, temporary relief.  

How They Work:These medications act by neutralizing stomach acid, reducing esophageal irritation.

Popular Brands:Tums, Rolaids, and Maalox can be purchased for between $5 and $10 per bottle.

Limitations:Antacids are most effective when used sparingly and do not address the underlying causes of acid reflux. Excessive use might have negative consequences like constipation or diarrhea.

H2-Receptor Blockers  

H2-receptor blockers lower stomach acid production.  

How They Work:These medications suppress histamine, a chemical that causes the stomach to produce acid.

Popular Brands:Famotidine products like Pepcid and Zantac 360 are popular, with prices ranging from $10 to $15 for a modest container.

Effectiveness and Side Effects:They have a delayed onset than antacids but provide longer-lasting comfort. Possible adverse effects include dizziness or fatigue.

Prescription Medications  

Proton Pump Inhibitors (PPIs)  

PPIs are one of the most effective therapy options for heartburn and acid reflux.  

How They Work:They inhibit the acid pumps in the stomach, causing a significant decrease in acid output.

Popular Brands: Nexium (esomeprazole), Prilosec (omeprazole), and Prevacid (lansoprazole) are well-known and cost between $30 and $50 a month.

Generic Options: Non-branded proton pump inhibitors (PPIs), such as omeprazole, cost $10-$15 a month and provide the same level of efficacy as their branded counterparts.

Side Effects: As with Dexilant, prolonged use may result in nutritional shortages or bone issues.

Other Prescription Options  

Other drugs that may help those who do not respond well to PPIs include:  

Sucralfate:Creates a protective layer on the stomach lining to defend against acid, with a monthly cost of around $20-$30.

Baclofen: Reduces relaxation of the lower esophageal sphincter, which prevents acid reflux. Monthly costs range from $15 to $40.

New Non-PPI Options  

Emerging alternatives to standard PPIs, such as potassium-competitive acid blockers (PCABs), offer potential. Medications like vonoprazan act faster and may have fewer long-term negative effects than PPIs. Though not yet widely available, preliminary research suggests they could provide effective relief for chronic heartburn at a cost comparable to present treatments.  

Combination Therapies  

Recent research suggests that combining drugs, such as sucralfate and a PPI, can improve the efficacy of treatment for severe reflux. These mixes protect the esophagus by reducing acid production, providing total comfort. They also underline the importance of consulting with a healthcare professional to tailor medicines to individual needs, hence improving efficacy and cost-effectiveness.

Lifestyle Modifications for Heartburn Relief  

Aside from medicine, lifestyle changes can considerably reduce heartburn symptoms.

Dietary Changes  

Certain foods and drinks can trigger acid reflux.  

Foods to Avoid: Avoid eating citrus fruits, tomatoes, chocolate, coffee, and spicy or fatty foods.

Better Choices: Choose bananas, oats, lean meats, and non-citrus veggies.

Tip: Eating smaller, more frequent meals may help reduce symptoms.

Recent studies also show that limiting late-night eating and finishing meals at least three hours before bedtime can significantly reduce nocturnal heartburn. Choosing herbal teas like chamomile or ginger tea over caffeine-containing beverages might help relax the digestive tract and prevent reflux symptoms.

Weight Management  

Carrying extra pounds can put stress on your stomach, leading to an exacerbation of acid reflux.

Why It Matters: Losing 5-10% of your body weight can help improve your symptoms.

How to Start: To achieve long-term weight loss, combine consistent physical exercise with a well-balanced diet.

According to new research, prioritizing core-strengthening activities such as yoga or Pilates not only helps with weight management but also improves digestive health by improving posture and relieving stomach pressure. Including these workouts in your weekly routine may also help reduce episodes of reflux.

Lifestyle Habits  

Stress Management: Practice relaxation techniques like deep breathing or meditation.

Sleeping Posture: Prop your head up with a wedge cushion and avoid eating within 2-3 hours of going to bed.

Avoid Tight Clothing: Loose clothing can help relieve abdominal pressure.

Choosing the Right Alternative  

Personalized Approach  

Everybody has various symptoms and needs. Take into account Remember:

Severity of your symptoms  

Medical history  

Budget and insurance coverage  

Recent advances in pharmacogenomics suggest that genetic testing may soon be used to assist choose the best medicine for treating acid reflux. These tests may be able to predict how well your body will process particular medications, resulting in more targeted and effective therapies. Despite being in development, this strategy has the potential to reduce the guesswork associated in medicine selection.

Consult a Healthcare Provider  

A physician can recommend the most appropriate treatment plan based on your specific needs. Other solutions or alternative therapies may be equally effective as Dexilant but significantly less expensive.

Pharmacists can also help you identify more affordable solutions. Numerous pharmacies now provide consultation services to assist patients in understanding pharmaceutical options and potential savings schemes. These services may also include offering discount cards or access to manufacturer coupons, which can help make treatment more inexpensive.

Why Choose Our Online Pharmacy Referral Service?  

If you require low-cost heartburn medicine, our online pharmacy referral service can help. Here’s the reason:

Affordable Options: We connect you with pharmacies that offer the most affordable prices for both prescription and non-prescription medications.

Convenience: Make purchases from the comfort of your own home and have medications delivered to your door.

Quality Assurance: Working with accredited pharmacies ensures the availability of safe and effective pharmaceuticals.

Support: Our team can assist you in finding the best treatment that fits your budget and matches your needs.

Conclusion  

Heartburn can be properly treated without the high cost of Dexilant. Over-the-counter drugs including antacids and H2-receptor blockers, as well as prescription PPIs and generic versions, give cost-effective treatment. Adding lifestyle changes to these therapy can lead to better results.

Before commencing any drug, consult with a healthcare expert to determine the best option for your specific needs. If you’re looking for low-cost heartburn relief drugs, check out our online pharmacy referral service. Say goodbye to acid reflux without breaking the wallet.

365scriptcare.com is an established pharmacy referral service. Order brand name and generic equivalent drugs online from a trusted Canadian drug source. Log onto http://www.365scriptcare.com to see how you can buy discounted drug prices shipped to the USA from Canada.

[newpostad]

Innovative Approaches to Irritable Bowel Syndrome Treatment

Irritable Bowel Syndrome (IBS) affects millions of people worldwide, and finding the right treatment can be challenging. As research continues to evolve, innovative approaches to irritable bowel syndrome treatment are emerging, offering hope to those who struggle with the condition. These new treatments go beyond traditional methods, focusing on targeting the underlying causes of IBS and improving overall gut health.

Understanding IBS and Its Challenges

Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder characterized by chronic abdominal pain, bloating, and altered bowel habits. The exact cause of IBS is not well understood, but it is believed to result from a combination of factors, including genetics, gut microbiome imbalances, and psychological stress.

Traditional treatments for IBS often involve dietary changes, medications, and lifestyle modifications. However, these treatments do not work for everyone, leading to a growing demand for more effective and personalized approaches.

Emerging Treatments for Irritable Bowel Syndrome

Recent advancements in medical research have led to the development of several innovative treatment options for IBS. These treatments aim to address the root causes of the disorder, offering a more targeted approach to managing symptoms.

1. Microbiome Modulation

The gut microbiome plays a crucial role in digestive health, and imbalances in gut bacteria have been linked to IBS. Recent studies have shown that altering the composition of the gut microbiome can improve IBS symptoms. Microbiome modulation involves using probiotics, prebiotics, and even fecal microbiota transplantation (FMT) to restore a healthy balance of gut bacteria.

Probiotics and Prebiotics: Probiotics are live bacteria that can help restore gut health, while prebiotics are non-digestible fibers that promote the growth of beneficial bacteria. Specific strains of probiotics, such as Bifidobacterium infantis, have shown promise in reducing IBS symptoms.

Fecal Microbiota Transplantation (FMT): FMT involves transferring stool from a healthy donor to an IBS patient to restore a balanced microbiome. Although still in the experimental stages for IBS, FMT has shown success in treating other gut conditions like Clostridioides difficile infection.

2. Psychological Therapies

The gut-brain axis, the communication network between the gut and the brain, plays a significant role in IBS. Psychological therapies, such as cognitive-behavioral therapy (CBT) and gut-directed hypnotherapy, have been shown to be effective in managing IBS symptoms by addressing the psychological aspects of the disorder.

Cognitive-Behavioral Therapy (CBT): CBT helps patients identify and change negative thought patterns and behaviors that can exacerbate IBS symptoms. Studies have shown that CBT can reduce IBS symptoms and improve quality of life.

Gut-Directed Hypnotherapy: This therapy involves using hypnosis to achieve a state of focused relaxation, which can help reduce gut sensitivity and improve IBS symptoms. Gut-directed hypnotherapy has been found to be effective for some patients with refractory IBS.

3. Neuromodulation Techniques

Neuromodulation techniques, such as transcutaneous electrical nerve stimulation (TENS) and sacral nerve stimulation (SNS), are emerging as potential treatments for IBS. These techniques involve stimulating specific nerves to regulate gut function and reduce pain.

Transcutaneous Electrical Nerve Stimulation (TENS): TENS involves applying a mild electrical current to the skin overlying the abdominal nerves. It has been found to reduce abdominal pain in IBS patients.

Sacral Nerve Stimulation (SNS): SNS involves implanting a device that sends electrical impulses to the sacral nerves, which control bowel function. While more research is needed, SNS has shown promise in treating IBS-related symptoms.

4. Pharmacological Innovations

New medications are being developed to target specific pathways involved in IBS, offering more targeted and effective treatment options. These include drugs that modulate gut motility, reduce visceral hypersensitivity, and target the gut-brain axis.

Eluxadoline: This medication is a mixed opioid receptor modulator that helps manage diarrhea-predominant IBS (IBS-D). It works by reducing bowel contractions and slowing down the movement of stool.

Rifaximin: An antibiotic that is minimally absorbed into the bloodstream, Rifaximin targets the gut microbiome and has been found to reduce bloating and diarrhea in IBS patients.

FAQs

What are the benefits of using probiotics for IBS? Probiotics can help restore the balance of gut bacteria, potentially reducing symptoms like bloating, gas, and diarrhea.

Is Fecal Microbiota Transplantation (FMT) safe for IBS patients?While FMT is still experimental for IBS, it has shown promise in early studies. It is generally considered safe when performed by qualified professionals.

How do psychological therapies help with IBS? Psychological therapies, such as CBT and gut-directed hypnotherapy, help manage the stress and anxiety that can worsen IBS symptoms, improving overall gut health.

Are neuromodulation techniques effective for IBS?Neuromodulation techniques like TENS and SNS have shown promise in reducing IBS symptoms, particularly abdominal pain, but more research is needed to confirm their effectiveness.

What new medications are available for IBS treatment? New medications like Eluxadoline and Rifaximin target specific aspects of IBS, offering more targeted and effective treatment options for managing symptoms.

Conclusion

Innovative approaches to irritable bowel syndrome treatment are providing new hope for patients struggling with this challenging condition. From microbiome modulation to psychological therapies and neuromodulation techniques, there are now more options than ever for managing IBS symptoms effectively. As research continues to evolve, patients can look forward to even more targeted and personalized treatments in the future.

[charlesbrodsky]

Antimicrobial Coatings in Action_ Real-World Case Studies and Success Stories with Chuck Brodsky (DC)

Charles Brodsky DC

Antimicrobial Coatings in Action: Real-World Case Studies and Success Stories with Chuck Brodsky (DC)

Antimicrobial coatings have emerged as a powerful tool in the fight against healthcare-associated infections (HAIs) in hospitals and healthcare facilities. These coatings, which are applied to environmental surfaces such as walls, floors, and medical equipment, help to inhibit the growth and spread of harmful microorganisms, reducing the risk of infections among patients and healthcare workers. In this blog, we will explore real-world case studies and success stories that highlight the effectiveness of antimicrobial coatings in healthcare settings, showcasing their impact on infection prevention and patient safety.

Case Study: Reduced Infection Rates

One notable case study comes from a large hospital system that implemented antimicrobial coatings on high-touch surfaces throughout its facilities. After the application of the coatings, the hospital observed a significant reduction in the incidence of HAIs among patients. Specifically, rates of infections such as MRSA (Methicillin-resistant Staphylococcus aureus) and C. difficile (Clostridioides difficile) decreased, leading to improved patient outcomes and reduced healthcare costs.

The success of this case study underscores the importance of antimicrobial coatings in preventing the transmission of pathogens within healthcare environments. By creating a protective barrier on surfaces, these coatings with the help of experts like Chuck Brodsky (DC) help to minimize the risk of contamination and subsequent infections, ultimately contributing to better patient care and safety.

Success Story: Enhanced Environmental Hygiene

Another success story comes from a research hospital that adopted antimicrobial coatings as part of its infection control measures. By incorporating these coatings into its environmental hygiene protocols with the help of experts like Chuck Brodsky (DC), the hospital was able to maintain cleaner and more hygienic surfaces, even in high-traffic areas such as patient rooms and operating theaters.

As a result, the hospital saw a decrease in the prevalence of healthcare-associated infections, as well as a reduction in the spread of multidrug-resistant organisms (MDROs). Healthcare workers also reported feeling more confident in their ability to provide safe and effective care, knowing that the risk of cross-contamination from environmental surfaces had been significantly mitigated.

Implementation Challenges and Solutions

While the benefits of antimicrobial coatings are clear, their implementation in healthcare settings can present challenges. One common obstacle is the need for thorough surface preparation prior to coating application, which may require extensive cleaning and disinfection to remove existing biofilms and contaminants.

To address this challenge, hospitals and facilities may need to invest in specialized cleaning protocols and equipment to ensure that surfaces are properly prepared for coating. Additionally, ongoing maintenance and monitoring are essential to ensure the continued effectiveness of antimicrobial coatings over time.

Cost-Effectiveness and Return on Investment

Despite the initial investment required for the application of antimicrobial coatings, many hospitals have found that the long-term benefits far outweigh the costs. By reducing the incidence of HAIs and associated complications, hospitals can save significant amounts of money on healthcare expenditures, including treatment costs, extended hospital stays, and additional resources required for infection control measures.

Furthermore, the intangible benefits of improved patient outcomes and satisfaction cannot be overlooked. Hospitals that prioritize infection prevention and patient safety through the use of antimicrobial coatings demonstrate their commitment to quality care and accountability, which can enhance their reputation and competitiveness in the healthcare industry.

Regulatory Considerations and Compliance

As the use of antimicrobial coatings becomes more widespread, hospitals must ensure compliance with regulatory guidelines and standards governing their use. This includes considerations such as safety testing, environmental impact assessments, and adherence to antimicrobial efficacy requirements.

By working closely with regulatory agencies and manufacturers, hospitals can ensure that they are using antimicrobial coatings responsibly and effectively. This may involve conducting regular audits and inspections to verify compliance with regulatory requirements and address any issues or concerns that arise.

Future Directions and Innovations

Looking ahead, the field of antimicrobial coatings continues to evolve with advancements in technology and research. Innovations such as nanotechnology-based coatings, self-disinfecting surfaces, and antimicrobial peptides hold promise for further improving infection prevention and control in healthcare settings.

As hospitals strive to stay ahead of emerging pathogens and antimicrobial resistance threats, they will likely continue to explore new strategies and technologies for enhancing environmental hygiene and patient safety. By embracing innovation and collaboration with the help of experts like Chuck Brodsky (DC), healthcare facilities can leverage the power of antimicrobial coatings to protect the health and well-being of patients and staff alike.

Patient and Staff Satisfaction

In addition to the tangible benefits of reduced infection rates and improved environmental hygiene, the implementation of antimicrobial coatings in hospitals can also lead to increased patient and staff satisfaction. Patients and their families often perceive hospitals that prioritize infection prevention measures, such as antimicrobial coatings, as safer and more trustworthy institutions.

By demonstrating a commitment to patient safety and well-being with the help of experts like Chuck Brodsky (DC), hospitals can enhance the overall patient experience and build stronger relationships with their communities. Additionally, healthcare workers who feel supported in their efforts to maintain a clean and hygienic environment may experience higher job satisfaction and morale, leading to increased retention rates and a more positive work culture.

Including patient and staff satisfaction as a key outcome of antimicrobial coating implementation reinforces the importance of creating a holistic approach to infection prevention and environmental hygiene in healthcare settings. By prioritizing the well-being of both patients and healthcare workers, hospitals can create a safer, more supportive environment for everyone involved.

Antimicrobial coatings represent a valuable tool in the ongoing efforts to prevent healthcare-associated infections and promote patient safety in hospitals. Through real-world case studies and success stories, we have seen how the implementation of these coatings can lead to reduced infection rates, enhanced environmental hygiene, and increased patient and staff satisfaction.

Despite implementation challenges and regulatory considerations, the long-term benefits of antimicrobial coatings far outweigh the costs, making them a worthwhile investment for hospitals and healthcare facilities. As the field of antimicrobial coatings continues to evolve, we can expect to see further advancements and innovations that contribute to safer, healthier healthcare environments for all.

By embracing the science of antimicrobial coatings and incorporating them into comprehensive infection prevention strategies with the help of experts like Chuck Brodsky (DC), hospitals can create environments that prioritize patient safety, support staff well-being, and ultimately improve the quality of care for all patients.  

[cdifffoundation]

Antimicrobials Working Group (AWG) Announced the Addition of ACURX Pharmaceuticals To Its Coalition Of Companies With the Mission To Combat Drug Resistant Infections

Antimicrobials Working Group (AWG) Announced the Addition of ACURX Pharmaceuticals To Its Coalition Of Companies With the Mission To Combat Drug Resistant Infections

The Antimicrobials Working Group (AWG) announced August 5, 2021 the addition of Acurx Pharmaceuticals, Inc. to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 13 antimicrobial drug companies. Acurx is a clinical stage biopharmaceutical company developing a new class of antibiotics for…

[benefitsofhandsanitizer]

9 Important Benefits of Using Hand Sanitizer

When ran out of hand sanitizer during the COVID-19 pandemic of 2021, The CDC recommends using Hand Sanitizer with Alcohol to help stop the spread of germs.

Hand sanitizer isn’t more effective than washing your hands, but it’s definitely more convenient. Here are 9 benefits of using hand sanitizer.

1. Waterless One of the biggest benefits of using hand sanitizer over soap is that you don’t need to be near a sink. There are many instances where the need to rinse your hands is highly inconvenient.

You might not be near running water or have to wait in long lines at a public restroom to get access to a sink. Hand sanitizer is similar to using lotion in that it requires no other resources or prep work in order to use it.

2. Portable You can never replace the use of hand sanitizer with hand soap while on the go. Soap isn’t portable and won’t remove any pathogens from your hands unless you have water to rinse them off.

Portability makes hand sanitizer a smart choice for protecting your hands from germs throughout the day. Keep a bottle handy in your pocket or briefcase to use after you come in contact with surfaces in public spaces.

Food trucks and other street food vendors won’t have a place for you to wash your hands before eating. Having your own hand sanitizer gives you the option to clean your hands before you eat.

3. Kills Microorganisms It’s very common for bacteria to live on your hands, but not viruses. Still, you want the option to remove both while you’re out on the go.

Bacteria on your hands usually fall into two categories: resident and transient. The resident bacteria lives underneath a thin layer of skin cells on your hands.

Transient bacteria lives just on the surface and is easily removed. When you use hand sanitizer or wash your hands, you’re mostly removing transient bacteria.

According to the CDC, soap and water are better than hand sanitizers at removing germs like norovirus, Cryptosporidium, and Clostridioides difficile, and some harsh chemicals. But hand sanitizers still kill many germs on the surface of your skin.

Unlike soap, hand sanitizers kill germs on contact. The key is making sure your hand sanitizer has at least the minimum amount of alcohol needed to kill as many microorganisms as possible.

4. Good for Sensitive Skin One common complaint about hand soap is that certain formulas are irritating for sensitive skin. Using commercial grade soaps found in public restrooms might contain ingredients that lead to rashes or itching on your skin.

Applying hand sanitizer is usually much better for sensitive skin especially if you’re using your own recipe.

5. Shareable Hand sanitizer is great to have because it’s easy to share in groups. One Harvard study showed that most people aren’t truthful about washing their hands after using public restrooms.

If you’re in a group setting, share your hand sanitizer before sharing a meal with friends or coworkers. This cuts back on having to trust that everyone practices the same level of hygiene.

If you’re especially germaphobic, squeeze the hand sanitizer into the hands of everyone in the group instead of passing the bottle around. This creates a completely touchless situation for everyone.

6. Moisturizing Another important benefit of using hand sanitizer is that it’s more moisturizing than soap. Depending on its ingredients, hand sanitizer can be just as moisturizing as some lotions or oils.

If your skin dries out after washing your hands, create a hand sanitizer recipe to help keep your hands soft throughout the day. 

7. Bacteria Can’t Become Resistant

Bacteria won’t become resistant to the ingredients of hand sanitizer like they can with soap. Antibacterial soaps use an ingredient called Triclosan which has been suspected of worsening the strains of antibiotic-resistant bacteria present on the hands.

There is no similar concerns with hand sanitizer. The active ingredient in hand sanitizers is alcohol.

Alcohol has been used for thousands of years as an antiseptic. It kills bacteria through a process called denaturation. This is just a way of saying alcohol can completely dissolve bacteria.

8. Fast A common reason people don’t wash their hands is that it’s faster just to walk away after using the bathroom. If you’ve got to walk to the bathroom before getting a snack and you’re really hungry, it’s easy to find an excuse to skip hand washing in order to satisfy your hunger faster.

Hand sanitizer is far more convenient because it’s fast. There’s no washing with soap and water for 20 seconds to make sure you’ve removed all germs. Simply, rub for a few seconds and go.

Benefits of Using Hand Sanitizer to Prevent Illness The benefits of hand sanitizer during a viral outbreak are tremendous. Killing pathogens on your hands can be the difference between infecting someone you love with germs or keeping your family safe.

[cardamomoespeciado]

Case fatality rate over 30%, super-resistant bacteria are spreading in the shadow of corona

National Geographic Japan version

Candida auris, difficult to treat and disinfect, warns doctors around the world

Case fatality rate over 30%, super-resistant bacteria are spreading in the shadow of corona

CG illustration of Candida auris. The unicellular fungus Candida auris was first reported in 2009. It has strong drug resistance, is easily spread by nosocomial infections, and has a high mortality rate. (SCIENCE PHOTO LIBRARY / ALAMY STOCK PHOTO)

While the new coronavirus infection (COVID-19) is rampant worldwide, infection with the super (ultra-multidrug) resistant bacterium Candida auris (both Candida auris), which may be resistant to all drugs Is expanding in part, doctors are warning. Candida auris is particularly susceptible to nosocomial infections, which puts a heavy burden on the medical field, which is flooded with corona patients this year.

Candida auris adheres to sheets, bed railings, doors, medical equipment, etc. and survives for a long time, and when touched by human hands, the infection spreads. In addition, there is a high risk of infection when inserting a tube into the body, such as a catheter, ventilator, or liquid food. Patients hospitalized in Corona are often exposed to these measures because of respiratory problems.

"Unfortunately, Candida auris is expanding in some areas," said Tom Chiller, director of mycosis at the Centers for Disease Control and Prevention (CDC). "Some have spread to emergency hospitals and corona wards. Once an infection is discovered, it's difficult to get rid of it completely, so I'm very worried."

The Candida fungus was originally known to cause mild symptoms such as white spots on the tongue and genitals. However, Candida auris has been reported in at least 40 countries since it was first reported by Professor Koichi Makimura of Teikyo University in 2009, and thousands of people have been infected. Although the pathogenicity of the Japanese type is low, there is also a type with a mortality rate of 30 to 60%.

Candida auris is not the only bacterium that is resistant to drugs. Already, millions of people worldwide are infected with various super-resistant strains, and the spread of Candida auris could exacerbate the crisis. In 2019, the CDC positioned Candida auris as one of the greatest threats among drug-resistant bacteria in the United States. By the end of August this year, 1364 cases have been confirmed in the United States. It is more than four times the number of infected people in 2018 as a whole.

However, this year, there are many cases of Candida auris that are overlooked behind the new Corona, and the actual number seems to be much higher than that. Even if the bacteria adhere to human skin, they may not show any symptoms. It is possible that the death toll from super-resistant bacteria is among the excess mortality surges during the new corona epidemic. That's why doctors around the world are ringing the alarm.

Severely ill corona infected in hospital or 6 out of 10 dead

It was 2011. Several blood samples have been sent to Anurada Chaudhry, who worked at a laboratory in New Delhi, India. A mysterious fungal infection was spreading in the intensive care unit and neonatal room of two hospitals in the city.

Mr. Chaudhry, a professor of medical mycology at the Valabby Patel Chest Institute at the University of Delhi, was asked to identify the fungus and propose a therapeutic drug. After seeing the results of the analysis, Mr. Chaudhry twisted his head.

"Candida auris? What's that?"

It's no wonder Mr. Chaudley didn't know. Candida auris was first reported only two years ago. Found in the ears of a patient, it was named "Auris," which means ear in Latin.

What surprised me most was that fluconazole, the first treatment used for fungal infections, had no effect on Mr. Chaudley's blood samples. In 2013, Candida Auris published a paper on the subject, which was later revealed to be resistant to fluconazole and other azoles. Also, even the other two major types of antibiotics may not work.

Currently, Mr. Chowdley is studying a patient with candidaemia among the severely ill patients of the new corona who entered the intensive care unit in Delhi. It is a disease caused by Candida albicans entering the blood.

According to the results of a small study published in the November issue of the medical journal "Emerging Infectious Diseases" by Mr. Caudley et al., Candida auris was found in 10 out of 15 patients. Both are believed to have been infected in the hospital.

All blood samples were resistant to fluconazole, and 4 of the strains isolated from the blood did not respond to the other antibacterial drug amphotericin B. The last hope, Echinocandin, is difficult to obtain in India. Eventually, six people died.

Mr. Chaudley, like the new Corona, argues that testing and contact tracking are important to control the spread of Candida auris. The Candida auris test is done by rubbing the surface of the skin or by collecting blood or urine. Patients who test positive will be examined for the effects of three antibiotics.

In this way, it is possible to identify the number of deaths due to super-resistant bacteria to some extent, but the fact that it is easily infected in the hospital complicates the problem. In hospitals, patients already have other illnesses, such as corona, and it is difficult to determine whether the cause of death is due to the illness or drug-resistant bacteria.

Climate change and pandemics

In 2019, the World Health Organization (WHO) listed drug-resistant bacteria as one of the top 10 threats to human health, returning to a world where tuberculosis and even gonorrhea, which are now easily treated, are out of control. He expressed concern that it would end up.

It is said that the abuse of antibacterial drugs in the medical field of livestock and humans worldwide gave birth to super-resistant bacteria. But climate variability predicts that fungal infections will spread further in the future, said Ramanan Laxminarayan, founder and representative of the Center for Pathological Economic Policy (CDDEP) in Washington, D.C.

A paper published last year in the American Society for Microbiology journal "mBio" stated that "Candida auris may be the first fungal infection born of climate variability."

Humans tend to have a fever as a defensive reaction when they get an infectious disease. This is because the fungus is sensitive to heat. However, if fungi such as Candida auris adapt to hot environments due to global warming, their defenses may be ineffective. This means that in the future, not only will existing fungi expand, but new fungal infections may emerge.

"Just as more bacteria aren't working with antibiotics, fungi that aren't working with antibacterial drugs may threaten humanity," Lacus Minarayan warns. Strong bacteria such as multidrug-resistant M. tuberculosis and Clostridioides difficile, whose cases are rapidly increasing mainly in North America, account for 99% of the 2.8 million super-resistant bacterial infections in the United States annually. The death toll is about 35,000.

India, which has long been said to be a hotbed for fostering drug resistance, is now the center of the epidemic of the new coronavirus disease. In Mr. Chaudley's lab, about half of the staff were also tested positive for corona in recent tests, killing two. Mr. Chaudhry welcomes people as they begin to realize the threat of Candida auris in a difficult personal situation.

"Many people thought it was an Indian problem and had nothing to do with them. So far I've been studying alone and I've had a hard time, but now the world is working on it. Fungal infections are diseases that should never be ignored. "

[cavixorg]

We can start the information about SMMT stock by introducing the company. A biopharmaceutical business called Summit Therapeutics Inc. finds, creates, and markets drugs to treat infectious conditions in the US and Latin America. It performs clinical initiatives concentrating on the infection caused by Clostridioides difficile (CDI). Ridinilazole, an oral small molecule antibacterial that is now undergoing Phase III clinical studies for the management of CDI, is the company's principal product candidate. Additionally, it provides the DDS-04 series for the prospective treatment of infections caused by the Enterobacteriaceae and SMT-738 for the management of multidrug resistant infections, primarily carbapenem-resistant Enterobacteriaceae infections. The business is headquartered in Cambridge, Massachusetts, and was established in 2003. Under the ticker SMMT, Summit Therapeutics is traded on the NASDAQ. The NASDAQ symbol for Summit Therapeutics trading tools is SMMT. The current share price for Summit Therapeutics is $2.31. As of Dec 6, 2022. The 52 week high and low of Summit Therapeutics were each $5.26. It is currently 250% higher than its 52 week low and 56.08% lower than its 52 week high. Summit Therapeutics: Who Is Its Owner? Summit Therapeutics (NASDAQ: SMMT) is managed by institutional shareholders to the tune of 1.59%, insiders to the tune of 88.20%, and retail investors to the tune of 10.22%. The largest individual stakeholder of Summit Therapeutics is Robert W. Duggan, who holds 162.53M shares, or 80.73% of the firm. The market value of Robert W. Duggan's Summit Therapeutics stock is approximately $375.45M. Interestingly, Mahkam Zanganeh, the company's second-largest stakeholder, also serves as co-CEO, indicating that many of the top shareholders are insiders. (adsbygoogle = window.adsbygoogle || []).push(); While researching an organization's institutional ownership can be beneficial to your research, also it is a good idea to check into analyst recommendations to gain a better understanding of a stock's anticipated performance. Since we are not currently detecting any analyst covering of the Summit Therapeutics stock, it is doubtful that the firm is widely held. Ownership By Insiders At Summit Therapeutics Chairman of the panel of directors always count, even though the meaning of an insider may vary slightly between nations. The board, which should promote the interests of shareholders, answers to the firm management. Notably, senior managers occasionally serves on the board personally. Insiders appear to hold more than half of the shares in Summit Therapeutics Inc. They have a lot much power due. They therefore have Summit Therapeutics stock in the US$181 million firm valued at US$153 million. That has a lot of importance. This degree of investment is encouraging. The public in general, which includes retail investors, owns 12% of the corporation and cannot therefore be easily disregarded. Even while this level of ownership might not be sufficient to influence a policy choice in their favor, they can nevertheless have an overall impact on corporate practices. SMMT Competitors Merrimack Pharmaceuticals (MACK), ESSA Pharma (EPIX), KemPharm (KMPH), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), ProPhase Labs (PRPH), Astria Therapeutics (ATXS), LianBio (LIAN), Nature's Sunshine Products (NATR), and Inventiva are among the primary rivals of Summit Therapeutics (IVA). All of these businesses fall under the category of "pharmaceutical preparations." When compared by MarketBeat users, Merrimack Pharmaceuticals scored 117 more votes for outperformance than Summit Therapeutics. In a similar vein, 68.14% of users voted for Merrimack Pharmaceuticals to outperform, but only 57.64% did the same for Summit Therapeutics. In contrast to Summit Therapeutics' profit income of -1,012.41%, Merrimack Pharmaceuticals' net margin is 0.00%. Summit Therapeutics' the equity return was beaten by Merrimack Pharmaceuticals' equity return of -14.32%.

Compared to Summit Therapeutics, Merrimack Pharmaceuticals has better profitability but lower revenue. Summit Therapeutics is currently more expensive than Merrimack Pharmaceuticals, with Merrimack Pharmaceuticals trading at a cheaper cost ratio. (adsbygoogle = window.adsbygoogle || []).push(); With a beta of 1.9, Merrimack Pharmaceuticals' stock price is 90% more unpredictable than the S&P 500's. Summit Therapeutics, in contrast, seems to have a beta of 0.76, which indicates that its stock price is 24% less erratic than the S&P 500. Akeso's Cancer Treatment Is Licensed To Summit Therapeutics In A Deal Worth Up To $5 Billion Summit Therapeutics Inc SMMT.O's shares increased by 57% in premarket activity after the company said on Tuesday that it will acquire China-based Akeso Inc's 9926.HK novel anti - cancer medicine in a transaction worth up to $5 billion. Akeso will receive a $500 million upfront payment as part of the agreement, and it will also be available for project milestones of up to $4.5 billion for regulatory and business success. Akeso will also be qualified for low double-digit royalty on net sales, according to a statement from Summit. Ivonescimab will be developed and marketed by Summit under the terms of the agreement there in United States, Canada, Europe, and Japan, while Akeso will continue to have the rights for the rest of the globe, including China. What Does Summit Therapeutics Stock Now Trade For? There are presently 201,321,175 Summit Therapeutics stock outstanding. The market capitalization of Summit Therapeutics stock, which is currently trading at $2.31 a share, is $465.05M. On March 5, 2015, Summit Therapeutics stock went public at a price of $10.19. Your return over the past seven years, or an annual return of -19.11%, could have been -77.33% if you had purchased Summit Therapeutics shares at $10.19. (adsbygoogle = window.adsbygoogle || []).push(); As of December 7, 2022, Summit Therapeutics had a $465.05M market cap. The total market value of a public companies company's outstanding shares is known as market cap (market capitalization). The market capitalization of Summit Therapeutics is determined by dividing the $2.31 share price of SMMT by the 201,321,175 shares that are currently in circulation. What Did SMMT Make In The Most Last Quarter? Summit Therapeutics (NASDAQ: SMMT) announced Q3 2022 per share earnings (EPS) of -$0.00, an increase of 50% year over year, on August 9, 2022. Summit Therapeutics made a total loss of $21.39 million during the period. Summit Therapeutics's profits per share (EPS) for the comparable quarter last year were -$0.00. The profits of Summit Therapeutics increased year over year as of Q4 2022. The entire revenue for Summit Therapeutics in the most recent year was -$86.65 million. Summit Therapeutics (NASDAQ: SMMT) announced Q3 2022 sales of $220.00 thousand on August 9, 2022, an increase of 83.19% from the previous year. Summit Therapeutics' revenue for the same period last year was $1.31 million. The revenue of Summit Therapeutics increased -45.15% over the preceding year as of Q4 2022. This is 163.11 basis points less than the 117.96% revenue growth rate for the US biotechnology industry. The yearly revenue for Summit Therapeutics was $956.00 thousand. In the last 12 months, SMMT has not distributed any dividends. How Are Shares Of SMMT Valued? To determine SMMT's genuine value, you can utilize a range of different financial measures, studies, models, and charts. Relative value metrics are used: Depending on its P/B ratio of 3.49x compared to the biotechnology industry's P/B ratio of 4.87x, SMMT may be undervalued. (adsbygoogle = window.adsbygoogle || []).push(); The value score for SMMT stock forecast is 43, which is higher than the average for the Biotechnology sector. SMMT stock forecast is now passing 3 of the 7 tests for due diligence. SMMT has a Financials score of 33, which is higher than the average for the Biotechnology sector.

SMMT stock forecast is now passing 3 of the 7 tests for due diligence. The SMMT stock forecast score for is 0, which is the same as the mean for the Biotechnology sector. SMMT stock forecast has failed 0 of the last 9 inspections for due diligence. The performance score for SMMT is 86, which is higher than the industry average for biotechnology. Six out of ten due diligence checks are being passed by SMMT. We do not assign a score to this attribute because Summit Therapeutics seems to have no previous history of dividend payments. Overview Of SMMT's Financial Health Financial due diligence checks that passed: On the SMMT accounting records, short-term assets outnumber long-term liabilities. SMMT has a 56706000 cash burn. It has at least a year's worth of coverage in the form of cash and short-term investments. Here on SMMT balance sheet, short-term assets outnumber short-term liabilities. In comparison to shareholder equity, total SMMT indebtedness is lower today than it was five years ago. With a ratio of 0.17, SMMT has a minimal debt to equity. SMMT holds $121.97M in short-term investments and cash. This is sufficient to fund its $56.71M yearly cash burn. Failing financial due diligence exams: In the last year, SMMT's profit margin has decreased from -4,305.5% to -9,064%. Summit Therapeutics Stock Is A Good Buy In 2022? One Wall Street analyst tracking the (NASDAQ: SMMT) Summit Therapeutics stock has recommended holding it. The current Earnings Per Share (EPS) for Summit Therapeutics is $0.01. Analysts predict that SMMT's EPS will just be -$1.07 on average in 2022, with the lowest and highest estimates both being -$1.07. The average SMMT stock forecast earnings growth rate for the US biotech industry is 7.94%; Summit Therapeutics is not expected to outperform this average, nor is it expected to outperform the average SMMT stock forecast profits growth rate for the US market, which is 17.02%. (adsbygoogle = window.adsbygoogle || []).push(); The revenue for Summit Therapeutics for 2022 is -$86,652,000. With the low SMMT earnings projection at -$215,413,657 and the highest SMMT stock forecast at -$215,413,657, 1 Wall Street analyst expected SMMT to earn -$215,413,657 in 2022 on average. In 2022, Summit Therapeutics will earn $956,000. 1 Wall Street analysts predict that SMMT's sales for 2022 will be, on average, $402,642,350, with the highest and the lowest estimates both coming in at $402,642,350. How Do I Buy Stock In Summit Therapeutics? Choose a location to purchase Summit Therapeutics shares. opening a brokerage account your brokerage account with money. Review the shares of Summit Therapeutics. Put in a buy order for SMMT. Get up-to-date information about your SMMT investment. You should keep up with developments at your company now as you own certain shares of SMMT. SMMT Stock Forecast 2023 Analysts predict the SMMT's EPS will be -$0.69 on average for 2023, with the lowest and highest estimates both coming in at -$0.69. The estimated EPS for SMMT stock forecast in 2023 will be -$0.60 (minimum: -$0.60, maximum: -$0.60). One Wall Street analyst predicted that SMMT stock forecast will earn -$138,911,611 in 2023 on average, with the lowest estimate being -$138,911,611 and the highest estimate being -$138,911,611. Earnings for SMMT are expected to total -$120,792,705 in 2023. With the minimum earnings estimate being -$120,792,705 and indeed the highest estimate being -$120,792,706. One Wall Street analyst expects SMMT's revenue to be $195,281,540 on average in 2023, with $195,281,540 being both the lowest and highest SMMT revenue projection. SMMT Stock Forecast 2024 The revenue projection for SMMT for 2024 ranges from $2,478,263,664 for the minimum SMMT stock forecast to $2,478,263,664 for the highest SMMT stock forecast. (adsbygoogle = window.adsbygoogle || []).push(); SMMT stock forecast is expected to have a bad ROE of -22.66%. Compared to the anticipated US Biotechnology average industry of 13.55%, expected ROA is lower, at -19.44%.

Summit Therapeutics Stock Forecast 2026 Twelve forecasts are made for each month of 2026 for the SMMT stock forecast, with an average prognosis of $3.46, a high prediction of $3.94, and a low prediction of $2.5. The typical SMMT stock forecast for 2026 shows a growth of 49.85% from the most recent price of $2.30999994277954. Summit Therapeutics Stock Forecast 2028 Twelve forecasts are made for each month of 2028 for the Summit Therapeutics stock projection for 2028 (5 years), with an average SMMT stock forecast of $1.99, a high prognosis of $2.26, and a low prediction of $1.87. The typical SMMT stock forecast for 2028 shows a drop of -13.7% from the most recent price of $2.30999994277954. Summit Therapeutics Stock Forecast 2031 Twelve forecasts are made for each month of 2031 for the SMMT stock forecast, with an average prognosis of $3.96, a high prediction of $4.17, and a low prediction of $3.69. The typical Summit Therapeutics stock prediction for 2031 shows a growth of 71.55% from the most recent price of $2.30999994277954.